Literature DB >> 15285696

The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.

Michael I Mackness1, Paul N Durrington, Bharti Mackness.   

Abstract

The antioxidant activity of high density lipoprotein (HDL) is largely due to the paraoxonase (PON) 1 located on it. Experiments with transgenic PON1 knockout mice indicate the potential for PON1 to protect against atherogenesis. This effect of HDL in decreasing low density lipoprotein (LDL) lipid peroxidation is maintained for longer than that of antioxidant vitamins and could therefore be more protective. Several important advances in the field of PON research have occurred recently, not least the discovery that two other members of the PON gene family -PON2 and PON3 - may also have important antioxidant properties. Significant advances have been made in understanding the basic biochemical function of PON1 and the discovery of possible modulators of its activity. Case-control studies of PON1 activity and coronary heart disease (CHD) have shown a clear association between CHD and low serum PON1 activity. This relationship has been further strengthened by the publication of the first prospective study showing low serum PON1 activity to be an independent predictor of new CHD events. Furthermore, decreased CHD risk has been revealed by meta-analysis to be associated with the polymorphisms of PON1, which are most active in lipid peroxide hydrolysis. Although this is likely to be an underestimate of the true contribution of PON1 to CHD (because these polymorphisms explain only a small component of the variation in PON1 activity), it is important because genetic influences are unlikely to be confounded by other factors linked with both CHD and diminished PON1 activity. PON1 is being extensively researched and it is hoped that therapeutic approaches will emerge to increase its activity. Clinical trials of these, if successful, will not only provide a novel means of preventing atherosclerosis, but also provide a more satisfactory means of testing the oxidant hypothesis of atherosclerosis than antioxidant vitamin supplementation has proved to be. Copyright 2004 Adis Data Information BV

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285696     DOI: 10.2165/00129784-200404040-00002

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  33 in total

Review 1.  Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Authors:  Ozkan Gungor; Fatih Kircelli; Huseyin Toz
Journal:  Int Urol Nephrol       Date:  2012-06-06       Impact factor: 2.370

Review 2.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

3.  Correlation of serum arylesterase activity on phenylacetate estimated by the integrated method to common classical biochemical indexes of liver damage.

Authors:  Fei Liao; Xiao-yun Zhu; Yong-mei Wang; Yun-sheng Zhao; Lian-ping Zhu; Yu-ping Zuo
Journal:  J Zhejiang Univ Sci B       Date:  2007-04       Impact factor: 3.066

Review 4.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

Review 5.  Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Alejandro Gugliucci
Journal:  J Physiol Biochem       Date:  2011-04-12       Impact factor: 4.158

6.  Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome.

Authors:  James Kyle Taylor; Eric P Plaisance; A Jack Mahurin; Michael L Mestek; Jose Moncada-Jimenez; Peter W Grandjean
Journal:  Redox Rep       Date:  2014-09-02       Impact factor: 4.412

7.  Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis.

Authors:  Junji Watanabe; Christina Charles-Schoeman; Yunan Miao; David Elashoff; Yuen Yin Lee; George Katselis; Terry D Lee; Srinivasa T Reddy
Journal:  Arthritis Rheum       Date:  2012-01-09

8.  Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients.

Authors:  Aysegul Kudu Cobanoglu; Ozkan Gungor; Fatih Kircelli; Ekrem Altunel; Gulay Asci; Sureyya Suha Ozbek; Huseyin Toz; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2012-12-05       Impact factor: 2.370

9.  Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein.

Authors:  Junji Watanabe; Victor Grijalva; Susan Hama; Karen Barbour; Franklin G Berger; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Biol Chem       Date:  2009-05-11       Impact factor: 5.157

10.  Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women.

Authors:  Kazuhiko Kotani; Naoki Sakane; Yoshiko Sano; Kokoro Tsuzaki; Yukiyo Matsuoka; Kahori Egawa; Makiko Yoshimura; Chika Horikawa; Yoshinori Kitagawa; Yoshinobu Kiso; Satoshi Kimura; John Schulze; Jennifer Taing; Alejandro Gugliucci
Journal:  J Clin Biochem Nutr       Date:  2009-10-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.